Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 4/20 | 0.39 |
| ▸ | FNTB | P49356 | 4/20 | 0.39 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073295 | 0.88 | AR (0.41) | MAPTARLMNAPTGDR2CYP11B2 | |
| SCHEMBL3074152 | 0.87 | PTGDR2 (0.38) | MAPTARPTGDR2CYP11B2 | |
| SCHEMBL3074166 | 0.86 | AR (0.39) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL5487110 | 0.77 | KMT2A (0.40) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL5353839 | 0.76 | KMT2A (0.39) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL3077524 | 0.75 | ALDH1A1 (0.40) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL3069269 | 0.75 | ALDH1A1 (0.52) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL3085330 | 0.74 | AR (0.50) | GAAARPTGDR2CYP11B2 | |
| SCHEMBL3080596 | 0.74 | AR (0.53) | ALDH1A1GAAKMT2AMEN1MAPT | |
| SCHEMBL3074151 | 0.74 | AR (0.41) | ARPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | ALDH1A1 809/4885GAA 4868/4885KDM4E 1414/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | ALDH1A1 816/4885GAA 4868/4885KDM4E 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.